# Cancer Diagnostics * **Definition:** A field of medical diagnostics focused on accurately identifying and tracking cancer-related tissue samples through various advanced techniques and tests, including genomic sequencing, liquid biopsy, and imaging methods, often enhanced by artificial intelligence technology. * **Taxonomy:** Healthcare Topics / Cancer Diagnostics ## News * Selected news on the topic of **Cancer Diagnostics**, for healthcare technology leaders * 10.8K news items are in the system for this topic * Posts have been filtered for tech and healthcare-related keywords | Date | Title | Source | | --- | --- | --- | | 4/23/2025 | [**Liquid Biopsy in Cancer Diagnostics Market to Grow at a CAGR of ~17y 2032 with Advancements in Non-Invasive Testing - DelveInsight**](https://www.globenewswire.com/news-release/2025/04/23/3066740/0/en/Liquid-Biopsy-in-Cancer-Diagnostics-Market-to-Grow-at-a-CAGR-of-17-by-2032-with-Advancements-in-Non-Invasive-Testing-DelveInsight.html) | [[Globe Newswire]] | | 4/3/2025 | [**Circulating Tumor Cell (CTC) Market Analysis and Forecast 2025-2030 - Yahoo Finance**](https://finance.yahoo.com/news/circulating-tumor-cell-ctc-market-110400613.html) | [[Yahoo Finance]] | | 3/10/2025 | [**Asia-Pacific's Digital Diagnostics Market to Triple in Size by 2030 - Yahoo Finance**](https://finance.yahoo.com/news/asia-pacifics-digital-diagnostics-market-095300817.html) | [[Yahoo Finance]] | | 3/6/2025 | [**Global AI in Cancer Diagnostics Market to Observe Stunning Growth at a CAGR ~11y 2032 - DelveInsight**](https://www.globenewswire.com/news-release/2025/03/06/3038528/0/en/Global-AI-in-Cancer-Diagnostics-Market-to-Observe-Stunning-Growth-at-a-CAGR-11-by-2032-DelveInsight.html) | [[Globe Newswire]] | | 12/26/2024 | [**Uterine Cancer Diagnostics Market Review 2018-2023 and Forecast to 2030**](https://finance.yahoo.com/news/uterine-cancer-diagnostics-market-review-091800475.html) | [[Yahoo Finance]] | | 12/18/2024 | [**Three for 2025: What you need to know about agentic AI, cancer informatics and data ...**](https://www.healthcareitnews.com/news/three-2025-what-you-need-know-about-agentic-ai-cancer-informatics-and-data-security-imperatives) | [[Healthcare IT News]] | | 12/12/2024 | [**Health IT Business News - December 12, 2024**](https://www.healthitanswers.net/health-it-business-news-december-12-2024/) | [[Health IT Answers]] | | 12/2/2024 | [**Next Generation Cancer Diagnostics Business Research Report 2024-2030: Technological Advancements in ctDNA, CTC, and Circulating miRNA Testing Propel Market Growth - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20241202011489/en/Next-Generation-Cancer-Diagnostics-Business-Research-Report-2024-2030-Technological-Advancements-in-ctDNA-CTC-and-Circulating-miRNA-Testing-Propel-Market-Growth---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 11/27/2024 | [**AI in Healthcare News and Updates**](https://www.healthitanswers.net/ai-in-healthcare-news-and-updates-112724/) | [[Health IT Answers]] | | 11/27/2024 | [**Next Generation Cancer Diagnostics Business Research Report 2024 - Yahoo Finance**](https://finance.yahoo.com/news/next-generation-cancer-diagnostics-business-142100263.html) | [[Yahoo Finance]] | | 11/21/2024 | [**Blood Cancer Diagnostics Market to hit USD 22.2 billion by 2032, says Global Market Insights Inc.**](https://finance.yahoo.com/news/blood-cancer-diagnostics-market-hit-123000317.html) | [[Yahoo Finance]] | | 10/22/2024 | [**Cancer Diagnostics Device Industry Sector: Market Dynamics and Future Scenarios 2024**](https://www.linkedin.com/pulse/cancer-diagnostics-device-industry-sector-market-dynamics-future-azhnf) | [[Linkedin]] | | 9/29/2024 | [**FDA approves Siemens' 3D breast-imaging tech**](https://www.beckershospitalreview.com/radiology/fda-approves-siemens-3d-breast-imaging-tech/) | [[Beckers Hospital Review]] | | 9/25/2024 | [**Global Prostate Cancer Diagnostics Market to Observe Stunning Growth at a CAGR of ~12y 2030 - DelveInsight**](https://www.prnewswire.com/news-releases/global-prostate-cancer-diagnostics-market-to-observe-stunning-growth-at-a-cagr-of-12-by-2030--delveinsight-302258082.html) | [[PR Newswire]] | | 9/3/2024 | [**Global Gastric Cancer Diagnostics Market is Expected to Expand at a CAGR of ~7y 2030 - DelveInsight**](https://www.prnewswire.com/news-releases/global-gastric-cancer-diagnostics-market-is-expected-to-expand-at-a-cagr-of-7-by-2030--delveinsight-302236389.html) | [[PR Newswire]] | | 8/27/2024 | [**AI-First Approach to Cancer Diagnostics Earns Ibex Medical Analytics Notable Milestones**](http://www.businesswire.com/news/home/20240827528282/en/AI-First-Approach-to-Cancer-Diagnostics-Earns-Ibex-Medical-Analytics-Notable-Milestones/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 8/27/2024 | [**AI-First Approach to Cancer Diagnostics Earns Ibex Medical Analytics Notable Milestones**](http://www.businesswire.com/news/home/20240827528282/en/AI-First-Approach-to-Cancer-Diagnostics-Earns-Ibex-Medical-Analytics-Notable-Milestones/?feedref=JjAwJuNHiystnCoBq_hl-Q-tiwWZwkcswR1UZtV7eGe24xL9TZOyQUMS3J72mJlQ7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LOzmn6JePCpHPCiYGaEx4DL1Rq8pNwkf3AarimpDzQGuQ==) | [[Business Wire]] | | 8/21/2024 | [**PreciseDx Raises $20.7M for AI-Powered Cancer Risk Assessments**](https://hitconsultant.net/2024/08/21/precisedx-raises-20-7m-for-ai-powered-cancer-risk-assessments/) | [[HIT Consultant]] | | 8/21/2024 | [**AI In Cancer Diagnostics Market Advancements Highlighted by Industry Research, Business ...**](https://www.whatech.com/og/markets-research/medical/869633-ai-in-cancer-diagnostics-market-2024-industry-research-business-trends-growth-analysis-and-forecast-to-2033.html) | whatech.com | | 7/21/2024 | [**Artificial Intelligence in Cancer Diagnostics Market Forecast- 2033**](https://www.alliedmarketresearch.com/artificial-intelligence-in-cancer-diagnostics-market-A323966) | alliedmarketresearch.com | | 7/12/2024 | [**United States Ovarian Cancer Diagnostics Market Research 2024: Analysis, Forecast and & Opportunities, 2019-2029 - Liquid Biopsies for Early Detection, Advancements in Molecular Diagnostics - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20240712611169/en/United-States-Ovarian-Cancer-Diagnostics-Market-Research-2024-Analysis-Forecast-and-Opportunities-2019-2029---Liquid-Biopsies-for-Early-Detection-Advancements-in-Molecular-Diagnostics---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 6/28/2024 | [**Genoks and Velsera Forge Strategic Partnership to Revolutionize Cancer Diagnostics in Turkey**](http://www.businesswire.com/news/home/20240628892797/en/Genoks-and-Velsera-Forge-Strategic-Partnership-to-Revolutionize-Cancer-Diagnostics-in-Turkey/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 6/28/2024 | [**Genoks and Velsera Forge Strategic Partnership to Revolutionize Cancer Diagnostics in Turkey**](https://finance.yahoo.com/news/genoks-velsera-forge-strategic-partnership-050400903.html) | [[Yahoo Finance]] | | 6/28/2024 | [**Genoks and Velsera Forge Strategic Partnership to Revolutionize Cancer Diagnostics in Turkey**](http://www.businesswire.com/news/home/20240628892797/en/Genoks-and-Velsera-Forge-Strategic-Partnership-to-Revolutionize-Cancer-Diagnostics-in-Turkey/?feedref=JjAwJuNHiystnCoBq_hl-Q-tiwWZwkcswR1UZtV7eGe24xL9TZOyQUMS3J72mJlQ7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LOzmn6JePCpHPCiYGaEx4DL1Rq8pNwkf3AarimpDzQGuQ==) | [[Business Wire]] | | 6/13/2024 | [**Flinn Foundation-Sponsored Study Identifies Three Bioscience Growth Areas to Advance Innovation and Economic Growth in Greater Phoenix**](http://www.businesswire.com/news/home/20240613324046/en/Flinn-Foundation-Sponsored-Study-Identifies-Three-Bioscience-Growth-Areas-to-Advance-Innovation-and-Economic-Growth-in-Greater-Phoenix/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | ## Topic Overview (Some LLM-derived content — please confirm with above primary sources) ### Key Players - **Guardant Health, Inc.**: A leader in liquid biopsy testing, partnering with Agostino Gemelli University Polyclinic Foundation to enhance cancer diagnostics. - **NeoGenomics**: A leader in cancer genetics testing, specializing in comprehensive testing menus for various healthcare sectors. - **DELFI Diagnostics, Inc.**: A company focused on blood-based tests for early cancer detection using AI and machine learning. - **PreciseDx**: An innovative company in oncology diagnostics utilizing AI for morphology-driven disease analysis. - **Myriad Genetics**: Focuses on molecular diagnostic tests that inform treatment decisions and improve patient care. - **Ibex Medical Analytics**: Develops AI-powered diagnostic devices to assist pathologists in identifying cancers, particularly in prostate diagnostics. - **Qritive**: A digital pathology and AI company enhancing cancer diagnostics through AI integration. - **Paige**: A technology and healthcare company transforming cancer diagnostics through AI tools and computational pathology. - **Exact Sciences**: Enhances access to colorectal cancer screening through funding initiatives. - **Mindpeak**: A leader in AI-powered pathological solutions, enhancing cancer diagnostics through advanced algorithms. - **Ataraxis**: A pathology startup utilizing machine learning for breast cancer diagnostics. - **Alverno Laboratories**: The first laboratory in the Midwest to implement AI in routine clinical practice, enhancing cancer diagnostics. - **Guardant Health**: A precision oncology company focused on advanced blood and tissue tests to improve patient outcomes across the cancer care spectrum. - **Lunit**: A company specializing in AI-powered medical image analytics and biomarkers for cancer detection. - **Azra AI**: Utilizes AI for oncology workflow automation, improving cancer diagnosis and patient routing. - **BostonGene**: A company recognized for its AI-powered platforms that enhance drug development and clinical trials, facilitating personalized cancer care. ### Partnerships and Collaborations - **Guardant Health and Policlinico Gemelli**: Established an in-house liquid biopsy testing service in Italy to enhance cancer diagnostics. - **Guardant Health and Agostino Gemelli University Polyclinic Foundation**: Creating an in-house liquid biopsy testing service to enhance cancer diagnostics in Italy. - **Institut Curie and Ibex Medical Analytics**: Integrating AI tools to enhance diagnostic accuracy and efficiency for cancer care. - **Myriad Genetics and Lumea Inc.**: Integrating molecular diagnostic tests into Lumea's digital pathology platform to streamline cancer testing. - **Qritive and Roche**: Collaborated to enhance cancer diagnostics and treatment through AI integration. - **Ibex Medical Analytics and Quest Diagnostics**: Collaboration to validate AI technology in enhancing diagnostic workflows for prostate cancer. - **Leica Biosystems and Molecular Instruments**: Partnering to integrate RNA-ISH technology with existing staining systems to enhance cancer diagnostics. - **Pangea Laboratory and Unilabs**: Introducing the Bladder CARE™ Assay in Switzerland to improve access to bladder cancer diagnostics. - **BostonGene and Various Institutions**: Collaborating to enhance personalized cancer care through AI-driven multiomics platforms. - **CAREScan Mobile Screening project**: Led by Medical College of Wisconsin to provide community-based cancer screenings using AI-enabled telehealth. - **Roche and multiple AI collaborators**: Roche has integrated over 20 advanced AI algorithms from various collaborators to enhance cancer diagnostics. - **COTA and Texas Oncology**: Partnered to utilize machine learning in precision oncology. - **Lunit and BreastScreen New South Wales**: Integrated AI technology into a national cancer screening program for improved early breast cancer detection. - **Alverno Laboratories and Ibex Medical Analytics**: Launched the Ibex Breast platform for AI-powered cancer diagnostics to improve diagnostic accuracy. - **Renovaro and Nebul**: Collaboration to establish GEDi CUBE for enhancing early cancer detection through AI. - **Lunit and Volpara Health**: Merged to leverage AI-driven cancer detection and personalized care. - **Genoks and Velsera**: This partnership aims to integrate Velsera's Clinical Genomics Workspace into Genoks' cancer diagnostic services, enhancing accuracy in cancer detection and characterization. - **PQE Group and Project-COMFORT**: Public-private partnership aimed at revolutionizing blood collection and diagnostics. - **Mindpeak and Roche**: Integrated AI algorithms into Roche's Digital Pathology Open Environment to enhance patient care. - **Flatiron Health and Lifebit Biotech**: Expanded collaboration into Japan to enhance cancer care through secure access to real-world data. ### Innovations, Trends, and Initiatives - **Liquid Biopsy**: Emerging as a non-invasive method for cancer detection, allowing for early diagnosis and monitoring. - **Liquid Biopsy Technologies**: Advancements in liquid biopsy are enhancing diagnostic accuracy and enabling non-invasive cancer detection. - **Liquid Biopsies**: Emerging as a non-invasive method for cancer detection, allowing for earlier diagnosis. - **Next Generation Cancer Diagnostics (NGCD)**: The market for NGCD is projected to grow significantly, driven by advancements in personalized medicine and genomic technologies. - **Liquid Biopsy Testing**: The rise of liquid biopsy tests, such as Guardant360, is enhancing non-invasive cancer diagnostics. - **Gastric Cancer Diagnostics**: The increasing incidence of gastric cancer is driving demand for innovative diagnostic tools. - **Liquid Biopsy Techniques**: Innovations such as DELFI Diagnostics' FirstLook Lung blood test are improving lung cancer detection rates. - **AI in Cancer Diagnostics**: The integration of AI technologies is transforming cancer diagnostics, improving accuracy and efficiency. - **Next-Generation Sequencing (NGS)**: NGS technologies are being integrated into cancer diagnostics to improve detection and treatment personalization. - **TETRIS Technology**: Developed by NUS Institute for Health Innovation & Technology, it uses DNA barcodes to map protein interactions in tumor cells, enhancing cancer diagnostics. - **Advanced Tumor Profiling**: Technologies like Velsera's tumor profiling are crucial for personalized treatment options. - **Theranostics Consortium (Thera4Care)**: Aiming to enhance access to precision medicine for cancer treatment across Europe, focusing on combining therapeutic and diagnostic approaches. - **AI-Powered Pathology**: Companies like Paige and Mindpeak are developing AI solutions to assist pathologists in diagnosing cancer. - **AI-Powered Diagnostics**: AI tools are enhancing accuracy in medical imaging, pathology, and genomics, leading to improved diagnoses. - **Exosome Diagnostics**: The market is growing due to advancements in personalized medicine and exosome isolation technologies. ### Challenges and Concerns - **Shortage of Pathologists**: The increasing incidence of cancer and a shortage of pathologists necessitate efficient diagnostic solutions. - **Data Privacy and Security**: As cancer diagnostics increasingly rely on AI and data analytics, concerns about patient data privacy and security are paramount. - **Workforce Shortages**: The aging population is leading to increased demand for cancer diagnostics, exacerbating existing workforce shortages in healthcare. - **High Technology Costs**: The cost of advanced diagnostic technologies can hinder widespread adoption. - **Healthcare Costs**: Rising healthcare costs and reimbursement issues are challenges in the adoption of advanced diagnostic technologies. - **Regulatory Hurdles**: Navigating regulatory approvals for new diagnostic technologies can be challenging and time-consuming. - **Integration into Clinical Workflows**: Ensuring that new diagnostic technologies seamlessly integrate into existing clinical workflows remains a challenge. - **Regulatory Restrictions**: Concerns regarding the regulatory landscape affecting the adoption of AI in diagnostics. - **Reimbursement Models**: Challenges in establishing reimbursement frameworks for AI diagnostics. - **Understanding of Exosome Biology**: A lack of understanding in this area poses challenges for the growth of exosome diagnostics. - **Data Privacy**: Ensuring the privacy and security of patient data in AI and digital pathology applications remains a critical concern. - **Implementation Costs**: High costs and interoperability issues hinder the widespread adoption of precision medicine software. - **Integration into Clinical Practice**: The successful integration of AI tools into existing clinical workflows is essential for widespread adoption. - **Clinician Burnout**: Potential impact of AI on clinician workloads and the need for effective integration into existing workflows. - **Regulatory Compliance**: Companies like Ibex are focusing on achieving certifications such as IVDR to ensure compliance with medical device regulations. ## Related Topics [[Next Generation Cancer Diagnostics]]; [[Cancer Screening]]; [[Molecular Diagnostics]]; [[AI in Cancer Diagnostics]]; [[Clinical Diagnostics]]; [[Cancer Treatment]]; [[Cancer Therapy]]; [[Medical Diagnostics]]